Epigenomics in cancer management

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 255-265

  Costa, Fabricio F ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer management; DNA methylation; Epigenetics; Epigenomics; Genomics; Histone modifications; New technologies

Indexed keywords

3 DEAZANEPLANOCIN A; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; DNA; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; HISTONE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; N PHTHALOYLTRYPTOPHAN; PANOBINOSTAT; ROMIDEPSIN; SIRTINOL; SOLINZA; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RESEARCH; CANCER SURVIVAL; CHROMATIN STRUCTURE; CHRONIC MYELOID LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA MODIFICATION; DRUG MECHANISM; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN GENOME; LEUKEMIA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; PANCREAS CANCER; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; PROSTATE CANCER; REVIEW; SOLID TUMOR;

EID: 79251504319     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/CMR.S7280     Document Type: Review

References (106)

1. Venter JC, Adams MD, Myers E W, et al. The sequence of the human genome. Science. 2001;291(5507):1304-1351.
2. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analyses of the human genome. Nature. 2001;409(6822):860-921.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
4. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828-1837.
5. Levy S, Sutton G, Ng PC, et al. The diploid genome sequence of an individual human. PLoS Biol. 2007;5(10):e254.
6. Wang J, Wang W, Li R, et al. The diploid genome sequence of an Asian individual. Nature. 2008;456(7218):60-65.
7. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437(7063):1299-1320.
8. ENCODE Project Consortium. Identifcation and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799-816.
9. López-Maury L, Marguerat S, Bähler J. Tuning gene expression to changing environments: from rapid responses to evolutionary adaptation. Nat Rev Genet. 2008;(8):583-593.
10. Callinan PA, Feinberg A P. The emerging science of epigenomics. Hum Mol Genet. 2006;15 Spec No 1:R95-R101.
11. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11): 1148-1159.
12. Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methyla-tion in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res. 1983;43(8): 3493-3496.
13. Jones PA. Altering gene expression with 5-azacytidine. Cell. 1985; 40(3):485-486.
14. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20(1):85-93.
15. Pinto A, Zagonel V. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacy-tidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia. 1993;7 Suppl 1: 51-60.
16. Karon M, Sieger L, Leimbrock S, et al. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood. 1973;42(3):359-365.
17. Slamon DJ, Godolphin W, Jones LA. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-712.
18. Paik S, Kim C, Wolmark N. HER2 status and beneft from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358(13): 1409-1411.
19. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218): 66-72.
20. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009;462(7276):1005-1010.
21. Lee W, Jiang Z, Liu J, et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010; 465(7297):473-477.
22. Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010; 463(7278):184-190.
23. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463(7278):191-196.
24. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905.
25. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463(7279):360-363.
26. Butler D. Human genome at ten: science after the sequence. Nature. 2010;465(7301):1000-1001.
27. Kaye J. The regulation of direct-to-consumer genetic tests. Hum Mol Genet. 2008;17(R2):R180-R183.
28. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethy-lome. Hum Mol Genet. 2007;16 Spec No 1:R50-R59.
29. Feinberg A P, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983; 301(5895):89-92.
30. Costa FF, Paixão VA, Cavalher F P, et al. SATR-1 hypomethylation is a common and early event in breast cancer. Cancer Genet Cytogenet. 2006;165(2):135-143.
31. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415-428.
32. Esteller M. Cancer epigenomics: DNA methylomes and histone-modifcation maps. Nat Rev Genet. 2007;8(4):286-298.
33. Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene. 2002;21(35):5388-5393.
34. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4): 683-692.
35. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet. 2000;9(16):2395-2402.
36. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene. 2001;20(24):3139-3155.
37. Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethy-lation in human colorectal tumors is not associated with DNA methyl-transferase overexpression. Cancer Res. 1999;59(10):2302-2306.
38. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
39. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125(2):315-326.
40. Kustatscher G, Ladurner AG. Modular paths to 'decoding' and 'wiping' histone lysine methylation. Curr Opin Chem Biol. 2007;11(6): 628-635.
41. Strahl BD, Allis CD. The language of covalent histone modifcations. Nature. 2000;403(6765):41-45.
42. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodys-plastic syndromes. J Clin Oncol. 2010;28(13):2253-2258.
43. Lara E, Mai A, Calvanese V, et al. Salermide, a Sirtuin inhibitor with a strong cancer-specifc proapoptotic effect. Oncogene. 2009; 28(6):781-791.
44. Brown CG. The DNA sequencing renaissance and its implications for epigenomics. Epigenomics. 2009;1(1):5-8.
45. Wang RY, Gehrke CW, Ehrlich M. Comparison of bisulfte modifcation of 5-methyldeoxycytidine and deoxycytidine residues. Nucleic Acids Res. 1980;8(20):4777-4790.
46. Kaneda A, Takai D, Kaminishi M, et al. Methylation-sensitive representational difference analysis and its application to cancer research. Ann N Y Acad Sci. 2003;983:131-141.
47. Rhee M, Burns MA. Nanopore sequencing technology: research trends and applications. Trends Biotechnol. 2006;24(12):580-586.
48. Flusberg BA, Webster DR, Lee JH, et al. Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat Methods. 2010;7(6):461-465.
49. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol. 2006;310: 251-274.
50. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 2003;4(6):351-358.
51. Woodson K, O'Reilly KJ, Hanson JC, et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol. 2008;179(2):508-511.
52. Yu J, Cheng YY, Tao Q, Cheung KF, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 2009;136(2):640-651.
53. Kim DS, Kim MJ, Lee JY, et al. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer. 2007;110(12):2785-2792.
54. Costa FF, Verbisck NV, Salim AC, et al. Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene. 2004;23(7):1481-1488.
55. Verbisck NV, Costa ET, Costa FF, et al. ADAM23 negatively modulates av53 integrin activation during metastasis. Cancer Res. 2009;69: 5546-5552.
56. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-1354.
57. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and beneft from temozolomide in glioblastoma. N Engl J Med. 2005;352(10): 997-1003.
58. Seligson DB, Horvath S, Shi T, et al. Global histone modifcation patterns predict risk of prostate cancer recurrence. Nature. 2005;435(7046): 1262-1266.
59. Wurdinger T, Costa FF. Molecular therapy in the microRNA era. Pharmacogenomics J. 2007;7(5):297-304.
60. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA. 2008;105(36):13556-13561.
61. Costa FF, Seftor EA, Bischof JM, et al. Epigenetically reprogram-ming metastatic tumor cells with an embryonic microenvironment. Epigenomics. 2009;1(2):387-398.
62. Bartel D. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.
63. Ambros V. The functions of animal microRNAs. Nature. 2004; 431(7006):350-355.
64. Passetti F, Ferreira CG, Costa FF. The impact of microRNAs and alternative splicing in pharmacogenomics. Pharmacogenomics J. 2009; 9(1):1-13.
65. Richter-Larrea JA, Robles EF, Fresquet V, et al. Reversion of epigenet-ically-mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood. 2010. [Epub ahead of print].
66. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007;13(6):1634-1637.
67. Hamm CA, Xie H, Costa FF, et al. Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2-deoxycytidine results in increased tumorigenicity PLoS One. 2009;4(12):e8340.
68. Liang G, Gonzales FA, Jones PA, et al. Analysis of gene induction in human fbroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res. 2002;62(4): 961-966.
69. de Smet C, de Backer O, Faraoni I, et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A. 1996;93(14):7149-7153.
70. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle. 2006;5(19):2220-2222.
71. Gimsing P, Hansen M, Knudsen LM, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008;81(3):170-176.
72. Tan J, Cang S, Ma Y, et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;4:3-5.
73. Plimack ER, Kantarjian HM, Issa J P. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma. 2007; 48(8):1472-1481.
74. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007;25(29):4603-4609.
75. Fiskus W, Wang Y, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009;114(13):2733-2743.
76. Kakihana M, Ohira T, Chan D, et al. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol. 2009;4(12):1455-1465.
77. Gupta M, Ansell SM, Novak AJ, et al. Inhibition of histone deacety-lase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood. 2009;114(14):2926-2935.
78. Chen S, Ye J, Kijima I, Evans D. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci USA. 2010;107(24):11032-11037.
79. Kauh J, Fan S, Xia M, et al. C-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One. 2010;5(4):e10376.
80. Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005;65(14):6305-6311.
81. Brueckner B, Rius M, Markelova MR, et al. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol Cancer Ther. 2010;9(5):1256-1264.
82. Chuang JC, Warner SL, Vollmer D, et al. S110, a 5-aza-2′-deoxycytidine-containing dinucleotide, is an effective DNA methyla-tion inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010;9(5):1443-1450.
83. Grant C, Rahman F, Piekarz R, et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010;10(7):997-1008.
84. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008;34(3):206-222.
85. Siegel D, Hussein M, Belani C, et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol. 2009;2:31.
86. Hrzenjak A, Kremser ML, Strohmeier B, et al. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by infuencing the mTOR pathway. J Pathol. 2008;216(4):495-504.
87. Alcaín FJ, Villalba JM. Sirtuin inhibitors. Expert Opin Ther Pat. 2009; 19(3):283-294.
88. Herman JG, Graff JR, Myöhänen S, et al. Methylation-specifc PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821-9826.
89. Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques. 2002;33(3):632-649.
90. Wu J, Smith LT, Plass C, Huang TH. ChIP-chip comes of age for genome-wide functional analysis. Cancer Res. 2006;66(14):6899-6902.
91. Park PJ. ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet. 2009;10(10):669-680.
92. Wang Y, Hayakawa J, Long F, et al. 'Promoter array' studies identify cohorts of genes directly regulated by methylation, copy number change, or transcription factor binding in human cancer cells. Ann N Y Acad Sci. 2005;1058:162-185.
93. van Steensel B, Henikoff S. Epigenomic profiling using microarrays. Biotechniques. 2003;35(2):346-350, 352-354, 356-357.
94. Mardis ER. The impact of next generation sequencing technology on genetics. Trends Genet. 2008;(3)133-141.
95. Kircher M, Kelso J. High-throughput DNA sequencing - concepts and limitations. Bioessays. 2010;32(6):524-536.
96. Branton D, Deamer DW, Marziali A, et al. The potential and challenges of nanopore sequencing. Nat Biotechnol. 2008;26(10): 1146-1153.
97. Eid J, Fehr A, Gray J, et al. Real-time DNA sequencing from single polymerase molecules. Science. 2009;323(5910):133-138.
98. Drmanac R, Sparks AB, Callow MJ, et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science. 2010;327(5961):78-81.
99. Ryan D, Rahimi M, Lund J, et al. Toward nanoscale genome sequencing. Trends Biotechnol. 2007;25(9):385-389. 100.
100. Wettergren Y, Odin E, Nilsson S, et al. p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer. Mol Med. 2008;14(7-8):412-421.
101. Leung RC, Liu SS, Chan KY, et al. Promoter methylation of death-associated protein kinase and its role in irradiation response in cervical cancer. Oncol Rep. 2008;19(5):1339-1345.
102. Liu M, Taketani T, Li R, et al. Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. Leuk Res. 2001;25(6):441-447.
103. Gazin C, Wajapeyee N, Gobeil S, et al. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature. 2007;449(7165): 1073-1077.
104. Seniski GG, Camargo AA, Ierardi D F, et al. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer. 2009;9:80.
105. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998;95(12):6870-6875.
106. Zhang H, Li Y, Lai M. The microRNA network and tumor metastasis. Oncogene. 2010;29(7):937-948.